Clinical Trial Update: To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) [Phase 3]

View source ↗

Summary

A Phase 3 trial (LIMBER-313) evaluating Parsaclisib in combination with Ruxolitinib for myelofibrosis was terminated, with results posted in October 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Post-essential Thrombocythemia Myelofibrosis
• Post-polycythemia Vera Myelofibrosis

Drugs mentioned

• Parsaclisib (parsaclisib)
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Incyte Corporation | Conditions: Myelofibrosis, Primary Myelofibrosis | Phase 3 | Status: TERMINATED | Results posted: 2024-10-04